SCHEMBL6402197

SCHEMBL6402197

O=C(CCCc1cccc(O)c1)c1cc(O)ccc1OP(=O)(O)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.43
AKR1B10 O60218 2/20 0.39
AKR1B1 P15121 2/20 0.39
ABCB1 P08183 7/20 0.39
MGLL Q99685 1/20 0.39
KCNH2 Q12809 1/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
PDE3A Q14432 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DPP4 P27487 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401793 0.93 ABCB1 (0.45) HDAC6ABCB1KCNH2KDM4EUSP2
SCHEMBL6403588 0.90 MEN1 (0.45) HDAC6AKR1B10AKR1B1MGLLDPP4
SCHEMBL6898518 0.89 MEN1 (0.48) ABCB1KCNH2KDM4EALDH1A1HPGD
SCHEMBL6399091 0.85 HIF1A (0.44) KDM4EUSP2ALDH1A1HPGDPDE3A
SCHEMBL6396603 0.82 MEN1 (0.53) HDAC6AKR1B10AKR1B1ABCB1MEN1
SCHEMBL6395137 0.82 ACHE (0.47) HDAC6MGLLALDH1A1MEN1KMT2A
SCHEMBL6398689 0.81 HDAC6 (0.46) HDAC6AKR1B10AKR1B1MGLLDPP4
SCHEMBL6401879 0.81 CBS (0.50) HDAC6AKR1B10AKR1B1KDM4EALDH1A1
SCHEMBL6404104 0.81 MEN1 (0.57) ABCB1KCNH2KDM4EALDH1A1HPGD
SCHEMBL6397196 0.80 MGLL (0.45) HDAC6AKR1B10AKR1B1MGLLDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 HDAC6 4653/4885AKR1B10 1004/4885AKR1B1 891/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 HDAC6 4532/4885AKR1B10 1016/4885AKR1B1 906/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 HDAC6 4653/4885AKR1B10 1004/4885AKR1B1 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.